Schlosser Mario sold $22.8M of OSCR

Schlosser Mario sold 750,000 shares of Oscar Health, Inc. (OSCR) at an average of $30.43 ($30.34–$30.79, $22.82M total) across 2 trades over 2026-08-27 to 2026-08-28.

Original reporting
SEC EDGAR · Schlosser Mario
Published Aug 31, 2026, 8:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 31, 2026, 9:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OSCR
Bearish
medium confidence
Mentioned
$OSCR
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OSCRBearishLow
01

Why it matters

The director's sale may be interpreted as a negative signal, but could also be a personal liquidity decision.

02

Market read

Primary insider sale; traders may adjust short positions or monitor price action.

03

What to watch

Potential upcoming capital raise or strategic transaction that requires cash.

Relevance 7/10Novelty 7/10Timing: after market close on 2026-08-31

Background

Form 4 filing provides the first public disclosure of the insider transaction.

Company-level read

Ticker impact

$OSCRBearishMedium confidence
Context

Director Mario Schlosser sold 750,000 shares for $22.8M, reducing his stake to 480,866 shares.

Expected impact

Potential short‑term downward pressure on OSCR price.

Evidence & confidence

The $22.8M sale represents a material reduction of insider ownership and is disclosed via a Form 4, which traders often view as a bearish signal.

Market effects

May raise concerns for the health‑tech sector if other insiders follow suit.

Limited to US markets where OSCR trades.

Minimal global impact beyond Oscar Health investors.

Counterpoint

The sale could be a routine liquidity event unrelated to company fundamentals.

Key entities

  • Oscar Health, Inc.

    US‑listed health‑tech insurer (NASDAQ: OSCR).

  • Mario Schlosser

    Director of Oscar Health who executed the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

$OSCRHighAI 8/10

What Oscar Health (OSCR) Said on Its Q3 Earnings Call

Oscar Health (OSCR) reported Q3 improvements in medical loss ratio (84%) and SG&A expense ratio (14%). The company raised its 2026 outlook, expecting $850M-$950M in earnings from operations and $19B-$19.3B in revenue. Membership grew 27% YoY to 2.7M, but is expected to decline to 2.5M by year-end due to disenrollments. Oscar plans to expand its footprint and products for 2027.

$OSCRMed

Oscar Health Inc (OSCR) Q3 2026 Earnings Call Highlights: Record Profitability, Raised

Oscar Health (OSCR) reported Q3 2026 earnings with record profitability and raised guidance. Membership declined due to CMS reviews, with more disenrollments expected. Q4 SG&A expenses are projected to rise due to seasonal spending. CEO Mark Bertolini and CFO Richard Blackley discussed market share gains, utilization trends, and CMS program integrity initiatives. The company anticipates stable membership and market growth despite competitive pressures and regulatory uncertainties.

$OSCRHighAI 8/10

Oscar Health (OSCR) Q3 2026 Earnings Call Transcript

Oscar Health (OSCR) reported Q3 2026 revenue of $5.1B, up 70% YoY, with membership at 2.7M, up 27% YoY. Net income was $167.3M, reversing a prior-year loss. The company raised full-year guidance for revenue, earnings, and adjusted EBITDA. Management highlighted expansion into new markets, product launches, and operational efficiencies.

$HCAMed

Hospital Stocks Soared as Democrats Took Congress

HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.